| | 公告日期 2024-05-08 | 异常期间 | 无 | | | | --- | --- | --- | --- | --- | --- | | | 天纺标(871753) 连续竞价 | 成交数量 | 5113235 | 成交金额（万 | 17975.19 | | | | （股） | | 元） | | | | 涉及事项 当日换手率达到20%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | | 5336657.71 | 4251475.1 | | 买2 | 东方财富证券股份有限公司拉萨金融城南环路证券营业部 | | | 3802553.25 | 2429130.18 | | 买3 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | | | 3492023.31 | 2876391.83 | | 买4 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | | | 3050293.77 | 2619088.38 | | 买5 | 东方财富证券股份有限公司 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-05- | 837023 | 芭薇股份 | 7606096 | 10685.08 | 当日收盘价涨幅达到29.96% | | 08 | | | | | | | 2024-05- 08 | 837023 | 芭薇股份 | 7606096 | 10685.08 | 当日价格振幅达到32.26% | | 2024-05- 08 | 833230 | 欧康医药 | 10321125.0 | 13242.17 | 当日换手率达到54.59% | | 2024-05- 08 | 837023 | 芭薇股份 | 7606096 | 10685.08 | 当日换手率达到31.78% | | 2024-05- 08 | 832471 | 美邦科技 | 7847426 | 10304.22 | 当日换手率达到27.45% | | 2024-05- 08 | 871753 | 天纺标 | 5113235 | 17975.19 | 当日换手率达到23.96 ...

| | 2024-05-07 公告日期 | 异常期间 | 无 | | | | --- | --- | --- | --- | --- | --- | | | 天纺标(871753) 连续竞价 | 成交数量 （股） | 4407345 | 成交金额（万 元） | 15019.94 | | | 涉及事项 当日换手率达到20%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | | 2632708.21 | 3720910.26 | | 买2 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | | | 2353813.76 | 3117372.51 | | 买3 | 国金证券股份有限公司成都双元街证券营业部 | | | 2175592.1 | 297166.08 | | 买4 | 东方财富证券股份有限公司昌都两江大道证券营业部 | | | 1785332.46 | 141090.7 | | 买5 | 东方财富证券股份有限公司拉萨金融城南环路证券营业部 | | | 176 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-05- 07 | 833230 | 欧康医药 | 7686410 | 9251.33 | 当日换手率达到40.65% | | 2024-05- | 837592 | 华信永道 | 4394400 | 7743.23 | 当日换手率达到25.65% | | 07 | | | | | | | 2024-05- | 832471 | 美邦科技 | 6769069 | 8144.52 | 当日换手率达到23.68% | | 07 | | | | | | | 2024-05- | 837006 | 晟楠科技 | 6357660 | 8605.16 | 当日换手率达到20.86% | | 07 | | | | | | | 2024-05- | 871753 | 天纺标 | 4407345 | 15019.94 | 当日换手率达到20.65% | | 07 | | | | | | ...

（一）基本情况 本公司董事会于 2024 年 5 月 6 日收到独立董事李姝女士递交的辞职报告，自 2024 年 5 月 6 日起辞职生效。上述辞职人员持有公司股份 0 股，占公司股本的 0%。不是失 信联合惩戒对象，辞职后不再担任公司其它职务。 （二）辞职原因 李姝女士因个人原因辞去公司独立董事职务，同时辞去董事会专门委员会的职 务。 证券代码：871753 证券简称：天纺标 公告编号：2024-054 天纺标检测认证股份有限公司独立董事辞职公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 一、辞职董监高的基本情况 李姝女士辞去独立董事职务不会对公司生产经营产生不利影响。公司将按照《公 司章程》等有关规定，尽快补选独立董事。李姝女士在担任公司独立董事期间勤勉尽 责，积极履行各项独立董事职责，公司对李姝女士在任职期间所做出的贡献表示衷心 的感谢！ 三、备查文件 李姝女士的《辞职报告》 天纺标检测认证股份有限公司 董事会 2024 年 5 月 7 日 二、上述人员的辞职对公司产生的影响 （一）本次辞职 ...

Financial Performance - Net profit attributable to shareholders increased by 301.59% to ¥1,796,660.38 from a loss of ¥891,236.86 in the same period last year[10]. - Operating revenue rose by 15.33% to ¥33,991,989.13, driven primarily by growth in testing income[11]. - Total revenue for Q1 2024 reached ¥33,991,989.13, an increase from ¥29,474,078.43 in Q1 2023, representing a growth of approximately 15.5%[32]. - The company’s net profit for Q1 2024 reached CNY 6,300,917.49, an increase of 35.0% compared to CNY 4,665,557.76 in Q1 2023[34]. - The total profit for Q1 2024 was CNY 7,374,907.65, compared to CNY 5,121,229.32 in Q1 2023, reflecting a growth of 43.9%[34]. - The company reported a total comprehensive income of CNY 6,300,917.49 for Q1 2024, compared to a loss of CNY 1,268,684.12 in the same period last year[36]. - Basic earnings per share for Q1 2024 were CNY 0.02, compared to a loss of CNY 0.01 per share in Q1 2023[34]. - The company reported a net profit margin of approximately -2.2% for Q1 2024, with net income impacted by increased operating costs[32]. Assets and Liabilities - Total assets decreased by 8.47% to ¥478,282,162.57 compared to the end of last year[10]. - Total assets decreased from CNY 522,530,811.65 as of December 31, 2023, to CNY 478,282,162.57 as of March 31, 2024, representing a decline of approximately 8.5%[26]. - Current assets decreased from CNY 302,702,660.00 to CNY 255,902,819.64, a reduction of about 15.5%[26]. - Cash and cash equivalents decreased from CNY 223,130,716.65 to CNY 177,488,702.00, a decline of approximately 20.5%[26]. - Total liabilities decreased to ¥16,297,607.08 from ¥22,132,094.77, reflecting a reduction of approximately 26.5%[31]. - Total current liabilities decreased from CNY 49,359,574.68 to CNY 41,424,580.78, a reduction of approximately 16.1%[27]. - Non-current liabilities increased from CNY 17,290,194.41 to CNY 21,797,478.56, an increase of about 26.5%[27]. - The company reported a significant increase in contract liabilities from CNY 3,078,056.97 to CNY 4,031,284.21, an increase of approximately 31%[27]. Cash Flow - Cash flow from operating activities decreased significantly by 88.24% to ¥1,230,747.10, mainly due to increased payments for wages and taxes[12]. - The net cash flow from operating activities for Q1 2024 was ¥595,427.27, a decrease of 92.0% compared to ¥7,473,505.98 in Q1 2023[39]. - Total cash inflow from operating activities was ¥35,469,028.65, up from ¥32,766,793.88 in the same period last year, representing an increase of 8.2%[38]. - Cash outflow from operating activities increased to ¥34,873,601.38, compared to ¥25,293,287.90 in Q1 2023, marking a rise of 37.8%[39]. - The net cash flow from investing activities was -¥45,795,559.00, significantly worse than -¥2,171,216.60 in Q1 2023[39]. - The net cash flow from financing activities was -¥144,563.43, a slight improvement from -¥1,003,098.11 in Q1 2023[39]. Shareholder Information - The number of ordinary shareholders is 6,638, with total share capital remaining at 81,404,368 shares[18]. - The largest shareholder, Tianjin Tianfang Investment Co., Ltd., holds 60.07% of the shares, totaling 48,902,903 shares[18]. Research and Development - Research and development expenses increased by 12.69% to ¥3,103,297.97, reflecting increased collaborative research efforts[12]. - The company invested ¥3,103,297.97 in R&D during Q1 2024, compared to ¥2,753,953.01 in Q1 2023, marking an increase of approximately 12.7%[32]. - Research and development expenses increased to CNY 2,406,759.57 in Q1 2024, a rise of 30.0% from CNY 1,850,120.27 in Q1 2023[34]. Corporate Governance - The company has no major litigation or arbitration matters reported during the period[22]. - There were no pledges or judicial freezes on shares held by major shareholders[20]. - The company has timely fulfilled its disclosure obligations regarding related party transactions and other significant transactions[22]. Future Outlook - The company plans to expand its market presence and invest in new technologies to drive future growth[32].

Financial Performance - The company achieved an operating revenue of 165 million RMB, representing a year-on-year growth of 16.31%[3] - The net profit attributable to the parent company, excluding non-recurring gains and losses, reached 31.29 million RMB, with a year-on-year growth rate of 12.86%[3] - The gross profit margin remained stable at 52.71%[3] - The net cash flow from operating activities was 47.73 million RMB, an increase of 6.82% compared to the same period last year[3] - The company's operating revenue for 2023 was CNY 165,893,296.70, representing a year-over-year increase of 16.31% compared to CNY 142,633,060.05 in 2022[26] - The net profit attributable to shareholders for 2023 was CNY 35,932,551.73, an increase of 8.79% from CNY 33,030,410.94 in 2022[26] - The gross profit margin for 2023 decreased to 52.71% from 53.98% in 2022[26] - The total assets at the end of 2023 were CNY 456,087,896.19, a 1.05% increase from CNY 451,365,062.90 at the end of 2022[27] - The total liabilities increased by 2.36% to CNY 32,522,289.86 in 2023 from CNY 31,772,545.30 in 2022[27] - The net assets attributable to shareholders rose to CNY 412,130,269.04, reflecting a 1.11% increase from CNY 407,596,217.18 in 2022[27] - The basic earnings per share for 2023 was CNY 0.44, down 12.96% from CNY 0.47 in 2022[26] - The cash flow from operating activities for 2023 was CNY 47,730,093.33, a 6.82% increase from CNY 44,682,941.43 in 2022[27] Research and Development - A total of 15 new patents were authorized, including 1 invention patent, and 34 internal R&D projects were initiated with an investment of 12.07 million RMB[4] - The company drafted 9 national and industry standards, along with over 40 enterprise standards[4] - Research and development expenses increased by 14.22% year-on-year, amounting to CNY 12.08 million[47] - The company has a total of 105 R&D personnel, accounting for 27.03% of the total workforce, up from 23.13%[74] - The company has developed a fully automatic soap liquid preparation system, which has completed trial use and meets the expected project standards for automatic configuration[77] - A new automatic online washing bottle system has been developed, which improves detection efficiency and reduces labor costs by implementing fully automated operations[78] - The company has created a new device for testing the water sweat stain color fastness, which is currently in the debugging phase and aims to replace manual processes[78] - A new evaporative rate testing device has been developed, with two prototypes completed, enhancing testing stability and allowing for data integration into ERP systems[79] - The company has established detection methods for harmful dyes in textiles, expanding its capabilities in environmental testing and compliance with international standards[79] Business Expansion and Strategy - The company expanded its business into special textiles and military-civilian integration, enhancing its service offerings[3] - The company plans to leverage its ten years of experience to continue innovation and reform for future growth[5] - The company aims to become a leading domestic and internationally recognized comprehensive testing institution, focusing on intelligent laboratory development and enhancing technological innovation capabilities[94] - The company plans to optimize its industrial layout by expanding into key regions such as East and South China, while enhancing capabilities in various sectors including e-commerce and medical devices[95] - The company is actively expanding its e-commerce platform business to cover various aspects of daily life[155] Corporate Governance and Management - The company has established new governance systems during the reporting period, ensuring compliance with relevant laws and regulations[159] - The company held 4 shareholder meetings during the reporting period, adhering to legal requirements for convening and voting procedures[161] - The company has implemented a comprehensive internal control system to protect the rights of all shareholders, especially minority shareholders[161] - The company has engaged professional managers to strengthen its management team and improve operational efficiency[159] - The company’s board consists of 9 members, including 3 independent directors, with 2 being accounting professionals[170] - The company has a performance evaluation mechanism for senior management, which is linked to the achievement of operational goals[185] Market Outlook and Industry Trends - The company expects the inspection and testing industry to grow, with projected revenue reaching 500 billion yuan by 2025[91] - By 2025, the number of personnel in the inspection and testing industry is expected to reach 1.7 million, with 790 million inspection reports issued[91] - The company anticipates that the inspection and testing market will maintain stable growth, with a forecast to exceed 450 billion yuan in 2023[91] - The inspection and testing industry in China is experiencing a trend towards industry concentration and specialization, driven by mergers, restructuring, and capital operations, aiming to enhance market efficiency and service quality[92] - The industry has maintained a rapid growth rate, supported by policy and market demand, with significant potential for future development, particularly in medical, biopharmaceutical, and food safety sectors[93] Risks and Challenges - The company faces risks related to internal management and resource integration as it scales, necessitating improvements in organizational structure and internal controls[99] - There is a significant risk of talent shortages in the testing industry, which could impact the company's development and competitive edge if not addressed[99] - The company emphasizes the importance of maintaining its credibility and brand reputation, as any damage could adversely affect customer trust and market position[99] - The company has not identified any new risk factors during the reporting period, indicating stability in its operational environment[100] Shareholder Information - The company has a total of 81,404,368 shares outstanding, with 5,162 shareholders[114] - The largest shareholder holds 48,902,903 shares, accounting for 60.07% of the total shares[115] - The company distributed a cash dividend of ¥30,119,616.16, amounting to ¥3.70 per 10 shares, based on a total of 81,404,368 shares[128] - The cash dividend policy was approved at the annual general meeting, ensuring compliance with company regulations and shareholder rights[129] - The company has maintained a transparent process for cash dividend distribution, ensuring that minority shareholders' rights are protected[129] Audit and Compliance - Key audit matters identified include revenue recognition, which is critical due to the inherent risks associated with improper revenue reporting[82] - The company implemented significant audit procedures related to revenue recognition, including evaluating internal controls and testing key control effectiveness[83] - The recoverability of accounts receivable was identified as a key audit matter due to its importance to the financial statements[84] - The audit report issued by Zhongzheng Huacai Accounting Firm confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2023[190] - The audit firm has been providing services to the company for 7 years, with an audit fee of 310,000 RMB[189]

天纺标检测认证股份有限公司 2023年财务报表审计报告 CAC 证审字[2024]0193 号 中审华会计师事务所 (特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://wc.mof.lg 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://sec.mol.gov.cn）"进行查验 目 录 | 들 录 | 页次 | | --- | --- | | 审计报告 r | 1-5 | | ເ ( 已审财务报表 | | | 合并资产负债表 | 6-7 | | 合并利润表 | 8 | | 合并现金流量表 | 9 | | 合并所有着权益变动表 | 10-11 | | 母公司资产负债表 | 12-13 | | 母公司利润表 | নি | | 母公司现金流量表 | 15 | | 母公司所有者权益变动表 | 16–17 | | 三、财务报表附注 | 18-110 | -- l 商计报告 CAC 证审字[2024] 0193 号 天纺标检测认证股份有限公司全体股东; 一、审计意见 我们审计了天纺标检测认证股份有限公司（以下简称贵公司）财务报表, 包括2023年12月31日的合 ...

中国银河证券股份有限公司 关于天纺标检测认证股份有限公司 2023年度募集资金存放与实际使用情况之核查意见 中国银河证券股份有限公司 （以下简称 "银河证券" 或 "保荐机构" ） 担任 夭纺标捡测认证股份有限公司 （以下简称 "天纺标"或 "公司" ） 向不特定合格 投资者公开发行股票的保荐机构， 根据（诬券发行上市保荐业务管理办法》、 《北 京证券交易所股票上市规则 （试行） 》 等相关法律、 法规和规范性文件的规定， 对天纺标2023年度募集资金存放与使用情况进行了专项核查， 井出其以下核查 意见： 一、 募集资金基本概况 （一） 实际募集资金金额、 资金到位情况 根据巾国证券监督管理委员会T 2022 年 9 月 27 日出具的"证监许可 [2022]2250 号"文 《关于同意天纺标检测认证股份有限公司向不特定合格投资者 公开发行股票汪册的批复》 ， 公司向不特定合格投资者发行人民币普通股股票 ]3-000，000.00股， 每股面值人民币 L00元， 每股澎壬价格为人民币 m，00元。 公 司本次公开发行股票募集资金总额为人民币 130，000.000.00元， 本次承销商、 上 市保荐人银河证券 ...

天纺标检测认证股份有限公司 2023年度募集资金存放与使用情况的 鉴证报告 CAC 证专字[2024] 0266号 中审华会计师事务所 (特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（birp://xc.mg.qqx.cn）"进行使用 "扫一扫"或进入"注册会计师行业统一监管平台（birp://xc.mg.qx.cn/）"进行评 7 目 录 目 页次 一、签证报告 1-2 二、附件 天纺标检测认证股份有限公司募集资 1-4 金存放与实际使用情况的专项报告 l = CAC 证专字[2024]0266 号 天纺标检测认证股份有限公司全体股东: 我们接受委托,对后附的天纺标检测认证股份有限公司(以下简称"天纺 标"） 编制的《天纺标检测认证股份有限公司2023年度募集资金存放与实际使 用情况的专项报告》(以下简称"募集资金专项报告")执行了合理保证的鉴 证业务。 我们认为，天纺标2023年度募集资金存放与使用情况专项报告在所有重大 方面按照中国证券监督管理委员会《上市公司监管指引第2号 -- 上市公司募集 资金管理和使用的监管要求（2022年修订）》（证监会公告（2022）15号）、 《 ...